Altus Pharmaceuticals Appoints Sheldon Berkle President and Chief Executive Officer.CAMBRIDGE, Mass. -- Altus(R) Pharmaceuticals Inc., a leader in the development of novel protein therapies to treat chronic gastrointestinal and metabolic diseases, announced today that Sheldon Berkle has been appointed President and Chief Executive Officer and a member of the Board of Directors. Mr. Berkle was most recently Executive Vice President of Boehringer Ingelheim Pharmaceuticals, Inc., where he was responsible for U.S. pharmaceutical operations, including portfolio management, new product launches, business development, and alliance management. "We are delighted to have Sheldon Berkle join Altus at this important moment in our development," said John Richard John D. Richard Q.C. (born July 30, 1934) is the Chief Justice of Canada's Federal Court of Appeal. Richard was born in Ottawa and received a Bachelor of Arts degree in Political Science from the University of Ottawa in 1955, followed by his law studies at Osgoode Hall Law , Chairman of the Board of Altus. "Shelly has an exceptional record of leadership in building successful pharmaceutical businesses. His experience and demonstrated strategic vision is a terrific fit with the breadth of commercial opportunity at Altus. Altus has an exciting pipeline, experienced senior management, and strong financial backers including Warburg Pincus, Nomura Phase4 Ventures, USVP USVP United States Venture Partners , and CMEA CMEA Council for Mutual Economic Assistance CMEA Cellular Message Encryption Algorithm CMEA Canadian Music Educators' Association CMEA Council for Mutual Economic Aid CMEA Certified Machinery Equipment Appraiser CMEA Colorado Music Education Association . Shelly has the right background to lead the Company through its next phase of commercial development and success, and on behalf of the Board, I welcome him to Altus." "With two products advancing in clinical trials and a strong preclinical pipeline, Altus is positioned to deliver important new therapies for GI and metabolic diseases. I have been impressed by the prospects for the Company's products and the quality and productivity of the Altus technology platform," commented Sheldon Berkle, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Altus. "Altus has accomplished a great deal over the past few years, and I look forward to leading the Company as we advance our innovative therapeutic products through the clinic and to the market." Sheldon Berkle previously held senior management positions of increasing responsibility culminating with Executive Vice President at Boehringer Ingelheim Pharmaceuticals, Inc (BIPI BIPI Boehringer Ingelheim Pharmaceuticals, Inc. BIPI Buscador Inteligente Para Internet (Spanish) ). At BIPI, Mr. Berkle was responsible for all aspects of U.S. pharmaceutical operations management. Prior to BIPI, Mr. Berkle was Chief Executive Officer and a co-founder of Boehringer Ingelheim Canada. Mr Berkle holds a BSc. in Pharmacy from the University of Manitoba Location The main Fort Garry campus is a complex on the Red River in south Winnipeg. It has an area of 2.74 square kilometres. More than 60 major buildings support the teaching and research programs of the university. and an M.B.A. from the University of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, . About Altus Pharmaceuticals Altus Pharmaceuticals is focused on developing and commercializing novel protein therapeutics for patients with chronic gastrointestinal and metabolic diseases. Altus' in-depth knowledge of protein crystallization Crystallization The formation of a solid from a solution, melt, vapor, or a different solid phase. Crystallization from solution is an important industrial operation because of the large number of materials marketed as crystalline particles. has resulted in a proprietary pipeline of orally delivered and injectable protein replacement products. As a company, Altus is committed to improving the quality of life of patients. More information about Altus and its clinical development programs can be found at www.altus.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion